Biofrontera Inc. (BFRI) Stock Analysis and Metrics

Biofrontera

NASDAQ: BFRI

$1.09 ▲ +0.00 (+0.00%)

At close: Jul 24, 2026 · 3:56 PM UTC

Financial Ratios

Market Cap11.04 Mn

P/E-1.33

P/S0.26

Div. Yield0.00

Revenue Growth (1y) (Qtr)36.16

Add ratio to table…

About

Biofrontera Inc. is a pharmaceutical company focused on the research development and commercialization of innovative dermatological treatments. The company specializes in photodynamic therapy solutions for skin conditions including actinic keratosis and other precancerous lesions. Its core activities center on bringing prescription dermatology products to market through regulatory approval and targeted sales efforts.

Biofrontera Inc. generates revenue primarily through the sale of its prescription dermatological products. The company earns income from product sales to healthcare providers and distributors who administer treatments to patients. Revenue is derived from commercializing FDA-approved therapies in the United States and select international markets.

The company operates through the following segments: Dermatology Products and Pharmaceutical Development.

• The Dermatology Products segment focuses on the commercialization and sale of approved topical treatments for skin conditions. This includes manufacturing marketing and distribution of prescription drugs such as Ameluz for photodynamic therapy. Activities involve regulatory compliance sales force management and market expansion efforts.

• The Pharmaceutical Development segment encompasses research and clinical trials for new dermatological formulations. This segment manages preclinical studies phase trials and regulatory submissions for pipeline products. It supports long term growth by advancing new candidates toward approval and market launch.

Biofrontera Inc. operates in a competitive specialty pharmaceutical landscape with established players in dermatology and photodynamic therapy. The company differentiates itself through its proprietary technology platform and focus on niche skin disease indications. Its competitive advantages include patent protected formulations and specialized knowledge in photodynamic treatment protocols.

Biofrontera Inc. serves dermatology clinics medical practices and healthcare distributors. Its products are used by dermatologists and physicians treating patients with actinic keratosis and related skin conditions. The company also works with specialty pharmacy partners to reach end users in the dermatology care setting.

Investment Thesis

▲ Bull case

Biofrontera is positioned to unlock significant growth from its expanded clinical pipeline, particularly the supplemental New Drug Application for superficial basal cell carcinoma (sBCC) with a PDUFA date of September 28, 2026, which if approved would make Ameluz the first photodynamic therapy drug authorized to treat a cancer in the United States, creating a high-margin oncology indication that could substantially increase the total addressable market beyond its current actinic keratosis focus and leverage the existing installed base of RhodoLED lamps across dermatology practices, thereby accelerating revenue growth through cross-selling opportunities without requiring major new capital investment in infrastructure.
The company’s strategic transaction with Biofrontera AG, which transferred full U.S. rights to Ameluz and RhodoLED and replaced the prior transfer pricing model (25-35% of revenue) with a more favorable earnout structure (12-15% of net sales), has already driven gross margin expansion to approximately 80% in Q1 2026 from 62% in the prior year period, and this structural improvement is sustainable and scalable, meaning that as revenue grows from label expansions in sBCC, actinic keratosis on extremities/neck/trunk, and acne vulgaris, the company will benefit from operating leverage where incremental revenue flows disproportionately to the bottom line, potentially enabling adjusted EBITDA positivity and cash flow breakeven sooner than market expectations.
Despite near-term challenges, Biofrontera is building multiple concurrent growth vectors: the Phase III trial success for actinic keratosis on the trunk, neck, and extremities (with a planned supplemental NDA filing in Q3 2026) addresses a large underserved population of approximately 58 million American adults with at least one actinic keratosis lesion, while the encouraging Phase II acne vulgaris data (58% reduction in inflammatory lesions vs. 37% for vehicle) provides a clear path to Phase III discussions with the FDA in late 2026, and together these indications could expand the treatable field size up to 240 square centimeters, significantly increasing utilization per patient and driving higher unit volumes of both Ameluz gel and lamp usage, which management is already preparing for through commercial readiness initiatives ahead of potential approvals.
The company has demonstrated improving financial execution, with cash used in operations declining to just $70,000 in Q1 2026 from $4.1 million in the prior year period, reflecting not only the benefit of the new cost structure but also favorable working capital trends and disciplined expense management, and while the balance sheet still requires careful monitoring, the combination of revenue growth, gross margin expansion, and potential near-term milestone payments (such as the $1 million from the Xepi divestiture) reduces near-term liquidity risk and supports the path to sustained profitability without requiring dilutive financing, especially if clinical milestones are met on schedule.

Biofrontera is positioned to unlock significant growth from its expanded clinical pipeline, particularly the supplemental New Drug Application for superficial basal cell carcinoma (sBCC) with a PDUFA date of September 28, 2026, which if approved would make Ameluz the first photodynamic therapy drug authorized to treat a cancer in the United States, creating a high-margin oncology indication that could substantially increase the total addressable market beyond its current actinic keratosis focus and leverage the existing installed base of RhodoLED lamps across dermatology practices, thereby accelerating revenue growth through cross-selling opportunities without requiring major new capital investment in infrastructure.
The company’s strategic transaction with Biofrontera AG, which transferred full U.S. rights to Ameluz and RhodoLED and replaced the prior transfer pricing model (25-35% of revenue) with a more favorable earnout structure (12-15% of net sales), has already driven gross margin expansion to approximately 80% in Q1 2026 from 62% in the prior year period, and this structural improvement is sustainable and scalable, meaning that as revenue grows from label expansions in sBCC, actinic keratosis on extremities/neck/trunk, and acne vulgaris, the company will benefit from operating leverage where incremental revenue flows disproportionately to the bottom line, potentially enabling adjusted EBITDA positivity and cash flow breakeven sooner than market expectations.
Despite near-term challenges, Biofrontera is building multiple concurrent growth vectors: the Phase III trial success for actinic keratosis on the trunk, neck, and extremities (with a planned supplemental NDA filing in Q3 2026) addresses a large underserved population of approximately 58 million American adults with at least one actinic keratosis lesion, while the encouraging Phase II acne vulgaris data (58% reduction in inflammatory lesions vs. 37% for vehicle) provides a clear path to Phase III discussions with the FDA in late 2026, and together these indications could expand the treatable field size up to 240 square centimeters, significantly increasing utilization per patient and driving higher unit volumes of both Ameluz gel and lamp usage, which management is already preparing for through commercial readiness initiatives ahead of potential approvals.
The company has demonstrated improving financial execution, with cash used in operations declining to just $70,000 in Q1 2026 from $4.1 million in the prior year period, reflecting not only the benefit of the new cost structure but also favorable working capital trends and disciplined expense management, and while the balance sheet still requires careful monitoring, the combination of revenue growth, gross margin expansion, and potential near-term milestone payments (such as the $1 million from the Xepi divestiture) reduces near-term liquidity risk and supports the path to sustained profitability without requiring dilutive financing, especially if clinical milestones are met on schedule.

▼ Bear case

Biofrontera’s reliance on off-label use remains a material but unquantified risk, as management acknowledged during the Q&A that while they do not encourage such use and believe it is limited due to payer sensitivity, they have no access to clear data on the extent of off-label Ameluz utilization for actinic keratosis on the extremities, neck, and trunk — a critical gap because if off-label use is already widespread, the incremental value of the pending label expansion for these indications could be significantly diminished, reducing the anticipated revenue uplift from the supplemental NDA filing and undermining the investment thesis built around unmet demand in these areas.
Despite the positive Phase III results for actinic keratosis on the trunk, neck, and extremities, the company has not yet disclosed key details such as the durability of response, long-term safety profile, or comparative effectiveness against established therapies like cryotherapy or topical fluorouracil, and without this data, there is uncertainty about whether dermatologists will adopt Ameluz PDT at scale for these indications, especially given the procedural nature of PDT (requiring lamp equipment and clinic visits) versus the convenience of self-administered topical alternatives, which could limit uptake and slow commercialization even after regulatory approval.
The acne vulgaris program, while showing promising Phase II results, lacks clarity on the path forward, as management’s statement that they “got the information we need to go into Phase III” is speculative and contingent on FDA agreement, and if the agency requests additional Phase II work — particularly around dosing optimization, longer-term efficacy, or head-to-head comparisons with existing therapies like isotretinoin or topical retinoids — the timeline for potential approval could be delayed by 12-18 months or more, increasing development costs and pushing out revenue realization, all while the company continues to incur SG&A expenses tied to commercial preparation for indications that may not materialize as expected.
Biofrontera’s operating model remains dependent on achieving cash flow breakeven through revenue growth, but total operating expenses increased 10% year-over-year to $14.4 million in Q1 2026, driven by a 27% rise in selling, general and administrative costs due to sales force expansion, legal costs from patent-related claims, and assumed manufacturing-related overhead, and while gross profit improved, the company still reported an operating loss of $4.3 million and a net loss of $4.8 million, meaning that without accelerated and sustained revenue growth — which is not guaranteed given the competitive landscape in dermatology and the early stage of its pipeline expansions — the path to profitability remains fragile and contingent on flawless execution across multiple uncertain clinical and commercial fronts.

Biofrontera’s reliance on off-label use remains a material but unquantified risk, as management acknowledged during the Q&A that while they do not encourage such use and believe it is limited due to payer sensitivity, they have no access to clear data on the extent of off-label Ameluz utilization for actinic keratosis on the extremities, neck, and trunk — a critical gap because if off-label use is already widespread, the incremental value of the pending label expansion for these indications could be significantly diminished, reducing the anticipated revenue uplift from the supplemental NDA filing and undermining the investment thesis built around unmet demand in these areas.
Despite the positive Phase III results for actinic keratosis on the trunk, neck, and extremities, the company has not yet disclosed key details such as the durability of response, long-term safety profile, or comparative effectiveness against established therapies like cryotherapy or topical fluorouracil, and without this data, there is uncertainty about whether dermatologists will adopt Ameluz PDT at scale for these indications, especially given the procedural nature of PDT (requiring lamp equipment and clinic visits) versus the convenience of self-administered topical alternatives, which could limit uptake and slow commercialization even after regulatory approval.
The acne vulgaris program, while showing promising Phase II results, lacks clarity on the path forward, as management’s statement that they “got the information we need to go into Phase III” is speculative and contingent on FDA agreement, and if the agency requests additional Phase II work — particularly around dosing optimization, longer-term efficacy, or head-to-head comparisons with existing therapies like isotretinoin or topical retinoids — the timeline for potential approval could be delayed by 12-18 months or more, increasing development costs and pushing out revenue realization, all while the company continues to incur SG&A expenses tied to commercial preparation for indications that may not materialize as expected.
Biofrontera’s operating model remains dependent on achieving cash flow breakeven through revenue growth, but total operating expenses increased 10% year-over-year to $14.4 million in Q1 2026, driven by a 27% rise in selling, general and administrative costs due to sales force expansion, legal costs from patent-related claims, and assumed manufacturing-related overhead, and while gross profit improved, the company still reported an operating loss of $4.3 million and a net loss of $4.8 million, meaning that without accelerated and sustained revenue growth — which is not guaranteed given the competitive landscape in dermatology and the early stage of its pipeline expansions — the path to profitability remains fragile and contingent on flawless execution across multiple uncertain clinical and commercial fronts.

Peer Comparison

Companies in the Drug Manufacturers - Specialty & Generic

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	HLN	Haleon plc	88.07 Bn	103.29	6.00	11.45 Bn
2	TEVA	Teva Pharmaceutical Industries Ltd	35.75 Bn	23.02	2.06	16.63 Bn
3	ZTS	Zoetis Inc.	31.84 Bn	12.05	3.35	9.05 Bn
4	TAK	Takeda Pharmaceutical Co Ltd	27.18 Bn	-10.29	0.59	28.76 Bn
5	UTHR	UNITED THERAPEUTICS Corp	23.09 Bn	17.93	7.28	-
6	RDHL	RedHill Biopharma Ltd.	21.32 Bn	2,931.66	2.24	-
7	VTRS	Viatris Inc	19.96 Bn	-67.32	1.37	14.34 Bn
8	NBIX	Neurocrine Biosciences Inc	17.66 Bn	26.41	5.69	-

Research Tools

Developers

About

Investment Thesis

Product and Service Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Product and Service Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password